Supplementary Table 1.

Change from baseline in pre-bronchodilator FEV 1 at Week 32 (mITT

population).
　 Japanese subgroup Overall population
Placebo Mepolizumab Placebo Mepolizumab
IV SC IV SC
N=16 N=17 N=17 N=191 N=191 N=194
Pre-bronchodilator FEV1 (mL)
LS mean change from 145 (81.7) 48 (84.7) 26 (81.0) 86 (31.4) 186 (31.5) 183 (31.1)
baseline (SE)
Difference from placebo - -97 -119 - 100 98
(95% CI) (-336, 142) (-353, 114) (13, 187) (11, 184)
p-value - 0.418 0.307 - 0.025 0.028
CI, confidence interval; FEV1, forced expiratory volume in 1 second; IV, intravenous; LS, least squares;
mITT, modified intent-to-treat; SE, standard error; SC, subcutaneous.

Supplementary Table 2. Physician and patient assessment of response to therapy (mITT population).

　 Japanese subgroup Overall population

Placebo Mepolizumab Placebo Mepolizumab
IV SC IV SC
N=16 N=17 N=17 N=191 N=191 N=194
Physician assessment of response to therapy
Significantly improved 1 (6%) 1 (6%) 2 (12%) 18 (9%) 44 (23%) 60 (31%)
Moderately improved 3 (19%) 5 (29%) 3 (18%) 39 (20%) 51 (27%) 56 (29%)
Mildly improved 4 (25%) 5 (29%) 6 (35%) 44 (23%) 41 (21%) 35 (18%)
No change 7 (44%) 3 (18%) 3 (18%) 71 (37%) 36 (19%) 32 (16%)
Mildly worse 0 0 0 5 (3%) 2 (1%) 1 (<1%)
Moderately worse 0 0 1 (6%) 1 (<1%) 2 (1%) 1 (<1%)
Significantly worse 0 0 0 0 1 (<1%) 0
Missing 1 (6%) 3 (18%) 2 (12%) 13 (7%) 14 (7%) 9 (5%)
Patient assessment of response to therapy
Significantly improved 1 (6%) 4 (24%) 2 (12%) 37 (19%) 57 (30%) 78 (40%)
Moderately improved 3 (19%) 4 (24%) 5 (29%) 31 (16%) 43 (23%) 48 (25%)
Mildly improved 4 (25%) 4 (24%) 5 (29%) 40 (21%) 34 (18%) 30 (15%)
No change 5 (31%) 2 (12%) 3 (18%) 63 (33%) 40 (21%) 26 (13%)
Mildly worse 2 (13%) 0 0 6 (3%) 2 (1%) 3 (2%)
Moderately worse 0 0 0 2 (1%) 1 (<1%) 0
Significantly worse 0 0 0 0 1 (<1%) 0
Missing 1 (6%) 3 (18%) 2 (12%) 12 (6%) 13 (7%) 9 (5%)